Axentis Pharma AG

axentispharma.com

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA. To protect Axentis Pharma against loss and damage from malversations caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TWELVE CONSULTING GROUP ANNOUNCES PARTNERSHIP WITH CELONIS TO HELP CUSTOMERS IDENTIFY AND ELIMINATE PROCESS INEFFICIENCIES

Twelve Consulting Group, | February 11, 2022

news image

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management. This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity. Read More

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

news image

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

news image

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More

VIEWS AND ANALYSIS, PHARMA TECH

VIRPAX PHARMACEUTICALS REPORTS ON FDA PRE-IND RESPONSE FOR NOBRXIOL™ (FORMERLY VRP324)

Virpax Pharmaceuticals | December 15, 2022

news image

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utili...

Read More
news image

Pharmacy Market

TWELVE CONSULTING GROUP ANNOUNCES PARTNERSHIP WITH CELONIS TO HELP CUSTOMERS IDENTIFY AND ELIMINATE PROCESS INEFFICIENCIES

Twelve Consulting Group, | February 11, 2022

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management. This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity. Read More

news image

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More
news image

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More
news image

VIEWS AND ANALYSIS, PHARMA TECH

VIRPAX PHARMACEUTICALS REPORTS ON FDA PRE-IND RESPONSE FOR NOBRXIOL™ (FORMERLY VRP324)

Virpax Pharmaceuticals | December 15, 2022

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utili...

Read More